Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label study of oral insulin (ORMD-0801) in NASH with type 2 diabetes
2020-001046-19Phase 2Completed
- Sponsor
- Oramed Pharmaceuticals Inc.
- Start
- Jul 2020
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ORMD-0801 in metabolic dysfunction-associated steatohepatitis (MASH) and type 2 diabetes mellitus (T2DM), sponsored by Oramed Pharmaceuticals Inc. Primary endpoint: Safety of ORMD-0801 in NASH with type 2 diabetes mellitus. Started Jul 2020; status: completed.
02
Drugs
ORMD-0801
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2020-001046-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001046-19.